These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 35802295

  • 1. Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Otten T, Riemsma R, Wijnen B, Armstrong N, Stirk L, Gordon C, Ramaekers B, Kleijnen J, Joore M, Grimm S.
    Pharmacoeconomics; 2022 Sep; 40(9):851-861. PubMed ID: 35802295
    [Abstract] [Full Text] [Related]

  • 2. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Mistry H, Nduka C, Connock M, Colquitt J, Mantopoulos T, Loveman E, Walewska R, Mason J.
    Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
    [Abstract] [Full Text] [Related]

  • 3. Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Witlox WJA, Grimm SE, Riemsma R, Armstrong N, Ryder S, Duffy S, Carrera VH, Posadzki P, Worthy G, Pouwels XGLV, Ramaekers BLT, Kleijnen J, Joore MA, van Asselt ADI.
    Pharmacoeconomics; 2021 Feb; 39(2):171-180. PubMed ID: 33145711
    [Abstract] [Full Text] [Related]

  • 4. Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Grimm SE, Witlox W, Wolff R, Chalker A, Hiligsmann M, Wijnen B, Ahmadu C, Ryder S, Armstrong N, Duffy S, Syndikus I, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2022 May; 40(5):509-518. PubMed ID: 34664200
    [Abstract] [Full Text] [Related]

  • 5. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P, Simpson E, Hamilton J, Pollard D, Clowes M, Kaltenthaler E, Meiklejohn D, Morley N.
    Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
    [Abstract] [Full Text] [Related]

  • 6. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I, Ren S, Simpson E, Clowes M, Scott DL, Young A, Stevenson M.
    Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210
    [Abstract] [Full Text] [Related]

  • 7. Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Witlox W, Grimm S, Howick J, Armstrong N, Ahmadu C, McDermott K, Otten T, Noake C, Wolff R, Joore M.
    Pharmacoeconomics; 2023 Aug; 41(8):857-867. PubMed ID: 37129774
    [Abstract] [Full Text] [Related]

  • 8. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC, Blommestein HM, Riemsma R, Armstrong N, Clay FJ, Ross J, Worthy G, Severens J, Kleijnen J, Al MJ.
    Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
    [Abstract] [Full Text] [Related]

  • 9. Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Rose M, Shepherd J, Harris P, Pickett K, Lord J.
    Pharmacoeconomics; 2018 Nov; 36(11):1299-1308. PubMed ID: 29691773
    [Abstract] [Full Text] [Related]

  • 10. Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Grimm SE, Wijnen B, Riemsma R, Fayter D, Armstrong N, Ahmadu C, Brandts L, Misso K, Kirwan JR, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2021 Dec; 39(12):1397-1410. PubMed ID: 34448148
    [Abstract] [Full Text] [Related]

  • 11. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Morgan P, Woolacott N, Biswas M, Mebrahtu T, Harden M, Hodgson R.
    Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
    [Abstract] [Full Text] [Related]

  • 12. Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal.
    Pennington B, Ren S, Barton S, Bacelar M, Edwards SJ.
    Pharmacoeconomics; 2019 Aug; 37(8):985-993. PubMed ID: 30465228
    [Abstract] [Full Text] [Related]

  • 13. Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pouwels XGLV, Petersohn S, Carrera VH, Denniston AK, Chalker A, Raatz H, Armstrong N, Shah D, Witlox W, Worthy G, Noake C, Riemsma R, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2020 May; 38(5):431-441. PubMed ID: 31701471
    [Abstract] [Full Text] [Related]

  • 14. Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P, Carroll C, Stevens JW, Rawdin A, Grimm S, Clowes M, Kaltenthaler E, Ingram JR, Collier F, Ghazavi M.
    Pharmacoeconomics; 2017 Aug; 35(8):805-815. PubMed ID: 28176188
    [Abstract] [Full Text] [Related]

  • 15. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I, Stevenson M, Cooper K, Harnan S, Hamilton J, Clowes M, Carroll C, Harrison T, Saha S.
    Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
    [Abstract] [Full Text] [Related]

  • 16. Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
    Ramaekers BLT, Riemsma R, Tomini F, van Asselt T, Deshpande S, Duffy S, Armstrong N, Severens JL, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2017 Feb; 35(2):191-202. PubMed ID: 27566699
    [Abstract] [Full Text] [Related]

  • 17. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Fleeman N, Abdulla A, Bagust A, Beale S, Richardson M, Stainthorpe A, Boland A, Kotas E, McEntee J, Palmer D.
    Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
    [Abstract] [Full Text] [Related]

  • 18. Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Orozco Leal G, Armstrong N, Kernohan A, Ahmadu C, Coughlan D, McDermott K, Duffy S, O'Meara S, Robinson T, Vale L, Kleijnen J.
    Pharmacoeconomics; 2023 Jul; 41(7):741-750. PubMed ID: 36952138
    [Abstract] [Full Text] [Related]

  • 19. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
    Thielen FW, Büyükkaramikli NC, Riemsma R, Fayter D, Armstrong N, Wei CY, Huertas Carrera V, Misso K, Worthy G, Kleijnen J, Corro Ramos I.
    Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
    [Abstract] [Full Text] [Related]

  • 20. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B, Pandor A, Stevenson M, Hamilton J, Chambers D, Clowes M, Graham J, Kumar MS.
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.